A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma

Annals of Oncology

Volumn 24, Issue 12, 2013, Pages 3061-3065

  Sohal, D P S ^a   Mykulowycz, K ^a   Uehara, T ^a   Teitelbaum, U R ^a   Damjanov, N ^a   Giantonio, B J ^a   Carberry, M ^a   Wissel, P ^a   Jacobs Small, M ^a   O'Dwyer, P J ^a   Sepulveda, A ^a   Sun, W ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Biliary tract cancer; Cholangiocarcinoma; Epidermal growth factor receptor EGFR; Gemcitabine; Irinotecan; Panitumumab

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; IRINOTECAN; K RAS PROTEIN; PANITUMUMAB;

ADULT; ADVANCED CHOLANGIOCARCINOMA; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTICLE; BILE DUCT CARCINOMA; BILIRUBIN BLOOD LEVEL; CANCER PATIENT; CANCER SURGERY; CLINICAL ARTICLE; DEHYDRATION; DIARRHEA; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN TISSUE; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA;

BILIARY TRACT CANCER; CHOLANGIOCARCINOMA; EPIDERMAL GROWTH FACTOR RECEPTOR EGFR; GEMCITABINE; IRINOTECAN; PANITUMUMAB;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILE DUCT NEOPLASMS; CAMPTOTHECIN; CHOLANGIOCARCINOMA; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TREATMENT OUTCOME;

EID: 84888785225     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt416     Document Type: Article

References (25)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. AJCC. AJCC Cancer Staging Manual. New York: Springer, 2010.
3. Lee J, Park SH, Chang HM et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2012; 13: 181-188.
4. Sharma A, Dwary AD, Mohanti BK et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol 2010; 28: 4581-4586.
5. Aljiffry M, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World J Gastroenterol 2009; 15: 4240-4262.
6. Valle J, Wasan H, Palmer DH et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273-1281.
7. Xu L, Hausmann M, Dietmaier W et al. Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines. BMC Cancer 2010; 10: 302.
8. Yoon JH, Gwak GY, Lee HS et al. Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. J Hepatol 2004; 41: 808-814.
9. Yoshikawa D, Ojima H, Kokubu A et al. Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma. Br J Cancer 2009; 100: 1257-1266.
10. Yoshikawa D, Ojima H, Iwasaki M et al. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer 2008; 98: 418-425.
11. Tannapfel A, Sommerer F, Benicke M et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 2003; 52: 706-712.
12. Itoi T, Takei K, Shinohara Y et al. K-ras codon 12 and p53 mutations in biopsy specimens and bile from biliary tract cancers. Pathol Int 1999; 49: 30-37.
13. Laghi L, Orbetegli O, Bianchi P et al. Common occurrence of multiple K-RAS mutations in pancreatic cancers with associated precursor lesions and in biliary cancers. Oncogene 2002; 21: 4301-4306.
14. Sun W, Hewitt MR, Theobald MR et al. A phase 1 study of fixed dose rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancer. Cancer 2007; 110: 2768-2774.
15. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996; 17: 343-346.
16. Peeters M, Price TJ, Cervantes A et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28: 4706-4713.
17. Philip PA, Mahoney MR, Allmer C et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 2006; 24: 3069-3074.
18. Paule B, Herelle MO, Rage E et al. Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas. Oncology 2007; 72: 105-110.
19. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006; 6: 714-727.
20. Malka D, Fartoux L, Rousseau V et al. Gemcitabine and oxaliplatin (GEMOX) alone or in combination with cetuximab as first-line treatment for advanced biliary cancer: final analysis of a randomized phase II trial (BINGO). J Clin Oncol 2012; 31: 4127.
21. Jensen LH, Lindebjerg J, Ploen J et al. Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer. Ann Oncol 2012; 23: 2341-2346.
22. Faris JE, Zhu AX. Targeted therapy for biliary tract cancers. J Hepatobiliary Pancreat Sci 2012; 19: 326-336.
23. Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 2010; 7: 493-507.
24. Andersen JB, Spee B, Blechacz BR et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 2012; 142: 1021-1031.
25. Hezel AF, Deshpande V, Zhu AX. Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol 2010; 28: 3531-3540.